Book a Meeting

Anti-S. epidermidis LTA Antibody, Non-Fucosylated (BioBet-435ZP) (CAT#: BioBet-435ZP) Datasheet

Target
S. epidermidis LTA
Isotype
IgG1, κ
Description
Anti-S. epidermidis LTA Antibody, Non-Fucosylated (BioBet-435ZP) is a chimeric monoclonal IgG1, κ antibody against S. epidermidis LTA. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Staphylococcal sepsis in infants with low birth weight
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced S. epidermidis LTA antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
S. epidermidis LTA
Alternative Names
Pagibaximab; 595566-61-3; BSYX-A110; A110; HU96-110; Lipoteichoic acid; LTA; S. epidermidis LTA; Staphylococcus epidermidis lipoteichoic acid
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with LTA include Psoriatic Arthritis and Leprosy 4.
Related Pathways
Its related pathways are Apoptosis Modulation and Signaling and NF-KappaB Family Pathway.
Function
A trimeric cytokine that binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. It binds to TNFRSF3/LTBR in the form of heterotrimer with LTB. Lymphotoxins are produced by lymphocytes and are cytotoxic to a variety of tumor cells in vivo and in vitro.
Field of research
Cell Biology and Cellular Response antibody; Developmental Biology antibody; Neuroscience antibody; Signaling Transduction antibody
Post-translational modifications
Phosphorylation at Ser-416 inhibits enzymatic activity.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-435ZP
Host
Chimeric
Species Reactivity
S. epidermidis IgG1, κ
Description
ADCC-enhanced Pagibaximab is a non-fucosylated anti-S.epidermidis LTA therapeutic biobetter antibody.
Antibody Indication
Staphylococcal sepsis in infants with low birth weight

Staphylococcal sepsis in infants with low birth weight

Related Products

Anti-S. epidermidis LTA Antibody, On-Target (AES-0622-ZP980) (CAT#: AES-0622-ZP980)
Anti-S. epidermidis LTA Antibody, Recycling (AES-0622-ZP324) (CAT#: AES-0622-ZP324)
Anti-S. epidermidis LTA Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP652) (CAT#: AES-0622-ZP652)
Anti-S. epidermidis LTA Antibody, Highly Galactosylated (BioBet-GA-435ZP) (CAT#: BioBet-GA-435ZP)
Anti-S. epidermidis LTA Antibody, Half-Life Extended (AES-0622-ZP1308) (CAT#: AES-0622-ZP1308)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.